GB201322602D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB201322602D0 GB201322602D0 GBGB1322602.2A GB201322602A GB201322602D0 GB 201322602 D0 GB201322602 D0 GB 201322602D0 GB 201322602 A GB201322602 A GB 201322602A GB 201322602 D0 GB201322602 D0 GB 201322602D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (28)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
| NZ720178A NZ720178A (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| CA2933755A CA2933755C (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| JP2016541294A JP6437559B2 (ja) | 2013-12-19 | 2014-12-19 | Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン |
| CN201480069437.9A CN105829315B (zh) | 2013-12-19 | 2014-12-19 | 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 |
| RU2016123363A RU2691105C1 (ru) | 2013-12-19 | 2014-12-19 | Лекарственные соединения |
| DK14815843.9T DK3083625T3 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| AU2014369457A AU2014369457B2 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors |
| PL14815843T PL3083625T3 (pl) | 2013-12-19 | 2014-12-19 | Pirymidopirymidynony użyteczne jako inhibitory kinazy wee-1 |
| SM20180020T SMT201800020T1 (it) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinoni utili come inibitori della chinasi wee-1 |
| PT148158439T PT3083625T (pt) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonas úteis como inibidores da cinase wee-1 |
| MX2016007801A MX371108B (es) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. |
| US15/105,869 US9850247B2 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors |
| KR1020167019551A KR102405462B1 (ko) | 2013-12-19 | 2014-12-19 | Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논 |
| LTEP14815843.9T LT3083625T (lt) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonai, tinkami naudoti kaip wee-1 kinazės inhibitoriai |
| ES14815843.9T ES2650013T3 (es) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonas útiles como inhibidores de la quinasa Wee-1 |
| EP14815843.9A EP3083625B1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| SI201430580T SI3083625T1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors |
| BR112016014151-2A BR112016014151B1 (pt) | 2013-12-19 | 2014-12-19 | Pirirmidopirimidinonas úteis como inibidores de quinases wee-1 |
| HUE14815843A HUE037908T2 (hu) | 2013-12-19 | 2014-12-19 | Pirimodopirimidononok mint WEE-1 kináz inhibitorok |
| HRP20180080TT HRP20180080T1 (hr) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze |
| PCT/GB2014/053793 WO2015092431A1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| NO14815843A NO3083625T3 (enExample) | 2013-12-19 | 2014-12-19 | |
| SG11201603814TA SG11201603814TA (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| RS20171338A RS56731B1 (sr) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze |
| ZA2016/03337A ZA201603337B (en) | 2013-12-19 | 2016-05-17 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| IL245672A IL245672B (en) | 2013-12-19 | 2016-05-17 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| CY20181100041T CY1120035T1 (el) | 2013-12-19 | 2018-01-15 | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201322602D0 true GB201322602D0 (en) | 2014-02-05 |
Family
ID=50071157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1322602.2A Ceased GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9850247B2 (enExample) |
| EP (1) | EP3083625B1 (enExample) |
| JP (1) | JP6437559B2 (enExample) |
| KR (1) | KR102405462B1 (enExample) |
| CN (1) | CN105829315B (enExample) |
| AU (1) | AU2014369457B2 (enExample) |
| BR (1) | BR112016014151B1 (enExample) |
| CA (1) | CA2933755C (enExample) |
| CY (1) | CY1120035T1 (enExample) |
| DK (1) | DK3083625T3 (enExample) |
| ES (1) | ES2650013T3 (enExample) |
| GB (1) | GB201322602D0 (enExample) |
| HR (1) | HRP20180080T1 (enExample) |
| HU (1) | HUE037908T2 (enExample) |
| IL (1) | IL245672B (enExample) |
| LT (1) | LT3083625T (enExample) |
| MX (1) | MX371108B (enExample) |
| NO (1) | NO3083625T3 (enExample) |
| NZ (1) | NZ720178A (enExample) |
| PL (1) | PL3083625T3 (enExample) |
| PT (1) | PT3083625T (enExample) |
| RS (1) | RS56731B1 (enExample) |
| RU (1) | RU2691105C1 (enExample) |
| SG (1) | SG11201603814TA (enExample) |
| SI (1) | SI3083625T1 (enExample) |
| SM (1) | SMT201800020T1 (enExample) |
| WO (1) | WO2015092431A1 (enExample) |
| ZA (1) | ZA201603337B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10364247B2 (en) * | 2015-04-21 | 2019-07-30 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Preparation and use of novel protein kinase inhibitors |
| CA3003737C (en) * | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of making and using the same |
| CA3043945A1 (en) | 2016-11-16 | 2018-05-24 | Sui Xiong Cai | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones |
| US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
| CN110198943B (zh) * | 2017-01-23 | 2021-04-16 | 石家庄智康弘仁新药开发有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
| GB201703881D0 (en) * | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| SG11201908788YA (en) | 2017-03-31 | 2019-10-30 | Seattle Genetics Inc | Combinations of chk1- and wee1 - inhibitors |
| CN110914277B (zh) * | 2017-07-10 | 2022-08-09 | 上海瑛派药业有限公司 | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| AU2018347307A1 (en) | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2019085933A1 (zh) | 2017-11-01 | 2019-05-09 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的大环类化合物及其应用 |
| WO2019169065A2 (en) * | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| MX2021003531A (es) * | 2018-09-27 | 2021-07-21 | Betta Pharmaceuticals Co Ltd | Inhibidor de fgfr4 y su uso. |
| US12180184B2 (en) | 2018-10-26 | 2024-12-31 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof |
| EP3902805A4 (en) | 2018-12-28 | 2023-03-01 | SPV Therapeutics Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
| KR102697799B1 (ko) | 2019-03-22 | 2024-08-23 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | Wee1 억제제 및 이의 제조 및 용도 |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| CN113939296A (zh) | 2019-04-09 | 2022-01-14 | 诺维逊生物股份有限公司 | 杂环化合物及其用途 |
| EP3952879A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| HRP20241008T1 (hr) | 2019-04-30 | 2024-11-08 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Kristalni oblik spoja inhibitora wee1 i njegova uporaba |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CN115698006B (zh) | 2020-06-17 | 2024-03-29 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物 |
| EP4221710A4 (en) * | 2020-10-01 | 2024-09-18 | University of Washington | DRUG-LIKE MOLECULES AND METHODS FOR THERAPEUTIC TARGETING OF MICRORNA-21 |
| TW202239409A (zh) * | 2020-12-18 | 2022-10-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| MX2023007244A (es) * | 2020-12-18 | 2023-06-29 | Glaxosmithkline Ip Dev Ltd | Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8. |
| JP2024515318A (ja) | 2021-04-30 | 2024-04-08 | ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド | Ｗｅｅ－１阻害剤としての縮合環状化合物、その調製方法およびその使用 |
| WO2022270994A1 (ko) | 2021-06-25 | 2022-12-29 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| CN116462687B (zh) | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| CN116836184B (zh) * | 2022-03-25 | 2025-07-25 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| CN117402162A (zh) | 2022-07-13 | 2024-01-16 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005090344A1 (en) | 2004-03-15 | 2005-09-29 | F. Hoffmann-La Roche Ag | Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| JP5411847B2 (ja) | 2007-04-25 | 2014-02-12 | Ｍｓｄ株式会社 | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| MX2009013728A (es) | 2007-06-15 | 2010-01-25 | Banyu Pharma Co Ltd | Derivados de bicicloanilina. |
| EP2213673B1 (en) | 2007-10-23 | 2013-06-05 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| CA2745959A1 (en) * | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
| WO2010067886A1 (en) | 2008-12-12 | 2010-06-17 | Banyu Pharmaceutical Co.,Ltd. | Dihydropyrimidopyrimidine derivative |
| JP5886310B2 (ja) * | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
| AR084515A1 (es) * | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| JP2014530867A (ja) | 2011-10-20 | 2014-11-20 | アッヴィ・インコーポレイテッド | キナーゼのピリドピリミジノン阻害剤 |
| CA2864142A1 (en) * | 2012-02-23 | 2013-08-29 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
-
2013
- 2013-12-19 GB GBGB1322602.2A patent/GB201322602D0/en not_active Ceased
-
2014
- 2014-12-19 HU HUE14815843A patent/HUE037908T2/hu unknown
- 2014-12-19 WO PCT/GB2014/053793 patent/WO2015092431A1/en not_active Ceased
- 2014-12-19 AU AU2014369457A patent/AU2014369457B2/en active Active
- 2014-12-19 US US15/105,869 patent/US9850247B2/en active Active
- 2014-12-19 MX MX2016007801A patent/MX371108B/es active IP Right Grant
- 2014-12-19 CA CA2933755A patent/CA2933755C/en active Active
- 2014-12-19 BR BR112016014151-2A patent/BR112016014151B1/pt active IP Right Grant
- 2014-12-19 HR HRP20180080TT patent/HRP20180080T1/hr unknown
- 2014-12-19 PT PT148158439T patent/PT3083625T/pt unknown
- 2014-12-19 DK DK14815843.9T patent/DK3083625T3/en active
- 2014-12-19 NZ NZ720178A patent/NZ720178A/en unknown
- 2014-12-19 CN CN201480069437.9A patent/CN105829315B/zh active Active
- 2014-12-19 EP EP14815843.9A patent/EP3083625B1/en active Active
- 2014-12-19 SM SM20180020T patent/SMT201800020T1/it unknown
- 2014-12-19 RS RS20171338A patent/RS56731B1/sr unknown
- 2014-12-19 JP JP2016541294A patent/JP6437559B2/ja active Active
- 2014-12-19 PL PL14815843T patent/PL3083625T3/pl unknown
- 2014-12-19 KR KR1020167019551A patent/KR102405462B1/ko active Active
- 2014-12-19 RU RU2016123363A patent/RU2691105C1/ru active
- 2014-12-19 SI SI201430580T patent/SI3083625T1/en unknown
- 2014-12-19 NO NO14815843A patent/NO3083625T3/no unknown
- 2014-12-19 SG SG11201603814TA patent/SG11201603814TA/en unknown
- 2014-12-19 LT LTEP14815843.9T patent/LT3083625T/lt unknown
- 2014-12-19 ES ES14815843.9T patent/ES2650013T3/es active Active
-
2016
- 2016-05-17 IL IL245672A patent/IL245672B/en unknown
- 2016-05-17 ZA ZA2016/03337A patent/ZA201603337B/en unknown
-
2018
- 2018-01-15 CY CY20181100041T patent/CY1120035T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201322602D0 (en) | Pharmaceutical compounds | |
| GB201306610D0 (en) | Pharmaceutical compounds | |
| IL240846A0 (en) | drug combination | |
| AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
| GB201302927D0 (en) | Compounds | |
| ZA201602047B (en) | Pharmaceutical compounds | |
| AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| GB201312386D0 (en) | Pharmaceutical compounds | |
| EP2948457A4 (en) | COMPOUNDS | |
| GB201306794D0 (en) | Compounds | |
| IL244365A0 (en) | pharmaceutical preparation | |
| GB201317166D0 (en) | Pharmaceutical compounds | |
| GB201316791D0 (en) | Pharmaceutical Compounds | |
| GB201316780D0 (en) | Pharmaceutical compounds | |
| GB201315733D0 (en) | Pharmaceutical compounds | |
| GB201315734D0 (en) | Pharmaceutical compounds | |
| GB201312464D0 (en) | Pharmaceutical compounds | |
| GB201308781D0 (en) | Pharmaceutical compounds | |
| GB201308782D0 (en) | Pharmaceutical compounds | |
| GB201308780D0 (en) | Pharmaceutical compounds | |
| GB201321316D0 (en) | Pharmaceutical Compound | |
| GB201309405D0 (en) | Pharmaceutical compound | |
| GB201316662D0 (en) | Pharmaceutical Combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |